Yi Sun

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. Zhou X, Tan M, Nyati M, Zhao Y, Wang G, Sun Y. Blockage of neddylation modification stimulates tumor sphere formation in vitro and stem cell differentiation and wound healing in vivo. Proc Natl Acad Sci U S A. 2016;113:E2935-44 pubmed publisher
  2. Xie C, Tan M, Lin X, Wu D, Jiang Y, Tan Y, et al. The FBXW7-SHOC2-Raptor Axis Controls the Cross-Talks between the RAS-ERK and mTORC1 Signaling Pathways. Cell Rep. 2019;26:3037-3050.e4 pubmed publisher
    ..Collectively, the SHOC2-Raptor interaction triggers negative cross-talk between RAS-ERK and mTORC1 pathways, whereas FBXW7 regulates both pathways by targeting SHOC2 for ubiquitylation and degradation. ..
  3. Yang F, Xu J, Li H, Tan M, Xiong X, Sun Y. FBXW2 suppresses migration and invasion of lung cancer cells via promoting β-catenin ubiquitylation and degradation. Nat Commun. 2019;10:1382 pubmed publisher
    ..Collectively, our study demonstrates that FBXW2 inhibits tumor migration, invasion and metastasis in lung cancer cells by targeting β-catenin for degradation. ..
  4. Wang Y, Tan M, Li H, Li H, Sun Y. Inactivation of SAG or ROC1 E3 Ligase Inhibits Growth and Survival of Renal Cell Carcinoma Cells: Effect of BIM. Transl Oncol. 2019;12:810-818 pubmed publisher
    ..Collectively, our study provides the proof-of-concept evidence that RING components of CRL are attractive candidates for targeted therapy of RCC. ..
  5. Jia L, Sun Y. RBX1/ROC1-SCF E3 ubiquitin ligase is required for mouse embryogenesis and cancer cell survival. Cell Div. 2009;4:16 pubmed publisher
    ..Proc Natl Acad Sci USA. 2009; 106:6203-6208Jia L, Soengas MS, Sun Y. ROC1/RBX1 E3 ubiquitin ligase silencing suppresses tumor cell growth via sequential induction of G2-M arrest, apoptosis, and senescence. Cancer Res. 2009; 69:4974-82. ..
  6. Zhou W, Xu J, Tan M, Li H, Li H, Wei W, et al. UBE2M Is a Stress-Inducible Dual E2 for Neddylation and Ubiquitylation that Promotes Targeted Degradation of UBE2F. Mol Cell. 2018;70:1008-1024.e6 pubmed publisher
    ..Collectively, our study establishes a negative regulatory axis between two neddylation E2s with UBE2M ubiquitylating UBE2F, and two CRLs with CRL3 inactivating CRL5. ..
  7. Tan M, Li H, Sun Y. Inactivation of Sag/Rbx2/Roc2 e3 ubiquitin ligase triggers senescence and inhibits kras-induced immortalization. Neoplasia. 2015;17:114-23 pubmed publisher
  8. Xie C, Wei D, Zhao L, Marchetto S, Mei L, Borg J, et al. Erbin is a novel substrate of the Sag-βTrCP E3 ligase that regulates KrasG12D-induced skin tumorigenesis. J Cell Biol. 2015;209:721-37 pubmed publisher
  9. Zhang Q, Karnak D, Tan M, Lawrence T, Morgan M, Sun Y. FBXW7 Facilitates Nonhomologous End-Joining via K63-Linked Polyubiquitylation of XRCC4. Mol Cell. 2016;61:419-433 pubmed publisher
    ..Our study demonstrates one mechanism by which FBXW7 contributes to genome integrity and implies that inactivated FBXW7 in human cancers could be a strategy for increasing the efficacy of radiotherapy. ..

More Information

Publications12

  1. Zhou W, Xu J, Li H, Xu M, Chen Z, Wei W, et al. Neddylation E2 UBE2F Promotes the Survival of Lung Cancer Cells by Activating CRL5 to Degrade NOXA via the K11 Linkage. Clin Cancer Res. 2017;23:1104-1116 pubmed publisher
    ..i>Clin Cancer Res; 23(4); 1104-16. ©2016 AACR. ..
  2. Tan M, Xu J, Siddiqui J, Feng F, Sun Y. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis. Mol Cancer. 2016;15:81 pubmed
    ..Sag is an oncogenic cooperator of Pten-loss for prostate tumorigenesis. Targeting SAG E3 ligase may, therefore, have therapeutic value for the treatment of prostate cancer associated with Pten loss. ..
  3. Li H, Zhou W, Li L, Wu J, Liu X, Zhao L, et al. Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine. Neoplasia. 2017;19:509-518 pubmed publisher
    ..Our study demonstrates that neddylation modification is a valid target for PDAC, and provides the proof-of-concept evidence for future clinical trial of MLN4924-gemcitabine combination for the treatment of pancreatic cancer patients. ..